Phil Carroll and Kevin Hornsby are joined by Tim McCarthy, Chairman of Incanthera.

In this episode, we dive into a significant update from Incanthera on the launch of its Skin + CELL skincare line with Marionnaud in Switzerland and Austria. The initial production order of 25,000 units has impressively doubled twice to 100,000 units, boosting expected revenues from £2 million to approximately £4 million. With high demand and planned European and Asian rollouts, further orders are expected to drive revenues to exceed £10 million for the financial year ending March 31, 2025. Additionally, Incanthera has raised £4.1 million through an institutional investor-led subscription and share sale at 15p per share to support the increased production schedule. The company has also scheduled a General Meeting on June 20, 2024, to approve the necessary share authorities.

Tune in for an in-depth discussion on these exciting developments and what they mean for the future of Incanthera.

Disclaimer & Declaration of Interest

The information, investment views, and recommendations in this podcast are provided for general information purposes only. Nothing in this podcast should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussio